| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1803-MM, Maintenance, Len vs Len/Dara | 1 | N | 0 Screening | 1420 | 1448 | 0 | 0 | 0 | 0 | 0 | 08/13/2019 | 339 | 116 |
| 1448 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 2 | Y | 1 Lenalidomide | 674 | 0 | 0 | 0 | 0 | 0 | 08/13/2019 | |||||
| 2 Lenalidomide + Daratumumab | 664 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 1338 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 3 | Y | 3 Stop vs Continue Treatment | 343 | 68 | 48 | 22 | 9 | 6 | 08/13/2019 | |||||
| 343 | 68 | 48 | 22 | 9 | 6 | |||||||||
| S2005-WM, Prev. Untreated, I/R or Z v V/R | 1 | Y | 1 I+R | 92 | 10 | 1 | 0 | 0 | 0 | 0 | 01/05/2022 | 166 | 37 | |
| 2 I+R+Venetoclax | 1 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 3 V+R | 20 | 10 | 8 | 5 | 2 | 0 | ||||||||
| 6 I+R or Z | 14 | 14 | 11 | 5 | 3 | 0 | ||||||||
| 45 | 25 | 19 | 10 | 5 | 0 | |||||||||
| 2 | Y | 5 IR | 1 | 1 | 0 | 0 | 0 | 0 | 01/05/2022 | |||||
| 1 | 1 | 0 | 0 | 0 | 0 | |||||||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | 1 | Y | 1 VRD-R | 510 | 49 | 14 | 6 | 3 | 1 | 0 | 10/12/2023 | 259 | 82 | |
| 2 DRD-R | 52 | 17 | 10 | 4 | 1 | 0 | ||||||||
| 3 DRD-DR | 48 | 16 | 5 | 3 | 1 | 0 | ||||||||
| 149 | 47 | 21 | 10 | 3 | 0 | |||||||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | 1 | Y | 0 Induction | 142 | 55 | 30 | 14 | 8 | 3 | 1 | 07/01/2024 | 167 | 47 | |
| 55 | 30 | 14 | 8 | 3 | 1 | |||||||||
| 2 | Y | 1 Dara-VCD | 18 | 12 | 7 | 3 | 1 | 0 | 07/01/2024 | |||||
| 2 Melphalan + ASCT | 18 | 13 | 4 | 2 | 1 | 0 | ||||||||
| 36 | 25 | 11 | 5 | 2 | 0 | |||||||||
| 3 | Y | 3 Dara | 20 | 17 | 10 | 5 | 1 | 0 | 07/01/2024 | |||||
| 20 | 17 | 10 | 5 | 1 | 0 | |||||||||
| Yes | A062102-MMYEL, All Stg, Iberdomide Tx | 0 | E | Total Registrations | 2 | 1 | 1 | 0 | 0 | 0 | 10/17/2024 | 83 | 27 | |
| 2 | 1 | 1 | 0 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 1 | 1 | 1 | 0 | 0 | 0 | 10/17/2024 | |||||
| 1 | 1 | 1 | 0 | 0 | 0 | |||||||||
| EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) | 0 | E | Total Registrations | 66 | 5 | 4 | 1 | 0 | 0 | 05/27/2021 | 254 | 82 | ||
| 66 | 5 | 4 | 1 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 50 | 5 | 3 | 1 | 0 | 0 | 05/27/2021 | |||||
| 50 | 5 | 3 | 1 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 38 | 7 | 4 | 1 | 1 | 0 | 05/27/2021 | |||||
| 38 | 7 | 4 | 1 | 1 | 0 | |||||||||
| No | EAA173-MYEL, SMM, Rd +/- Daratumumab | 0 | E | Total Registrations | 91 | 11 | 6 | 3 | 2 | 0 | 01/08/2020 | 262 | 95 | |
| 91 | 11 | 6 | 3 | 2 | 0 | |||||||||
| 1 | E | Total Registrations | 46 | 7 | 3 | 2 | 1 | 0 | 01/08/2020 | |||||
| 46 | 7 | 3 | 2 | 1 | 0 | |||||||||